Table 3.
Recommended care during 18-month period by provider type (n = 12,016)
| Overall | Patients with liver-related visit (51 %)
|
Patients without liver-related visit | ||||||
|---|---|---|---|---|---|---|---|---|
| Specialist | PCP only | |||||||
|
|
|
|
|
|||||
| (n = 12,016) | (n = 1,676) | (n = 4,494) | (n = 5,846) | |||||
|
|
|
|
|
|||||
| n | % | n | % | n | % | n | % | |
| HBV disease monitoring | ||||||||
| ALT only | 4,595 | 38.2 | 158 | 9.4 | 2,090 | 46.5 | 2,347 | 40.1 |
| HBV DNA only | 79 | 0.7 | 8 | 0.5 | 47 | 1.0 | 24 | 0.4 |
| Both ALT and HBV DNA | 4,654 | 38.7 | 1,501 | 89.6 | 2,093 | 46.6 | 1,060 | 18.1 |
| (n = 7,256)
|
(n = 1,098)
|
(n = 2,934)
|
(n = 3,224)
|
|||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |
| HCC surveillance | ||||||||
| Imaging and AFP | 3,537 | 48.8 | 953 | 86.8 | 1,901 | 64.8 | 683 | 21.2 |
| Imaging alone | 541 | 7.5 | 57 | 5.2 | 240 | 8.2 | 244 | 7.6 |
| AFP alone | 686 | 9.5 | 58 | 5.3 | 383 | 13.1 | 245 | 7.6 |
| None | 2,492 | 34.3 | 30 | 2.7 | 410 | 14.0 | 2,052 | 63.7 |
Among surveillance candidates defined by AASLD-based criteria